首页> 外文期刊>Journal of clinical neuroscience: official journal of the Neurosurgical Society of Australasia >Neurothrombectomy for the treatment of acute ischemic stroke in 1530 patients
【24h】

Neurothrombectomy for the treatment of acute ischemic stroke in 1530 patients

机译:神经血栓切除术治疗急性缺血性卒中1530例

获取原文
获取原文并翻译 | 示例
           

摘要

Neurothrombectomy is being used increasingly for the treatment of acute ischemic stroke. To assess the recanalization rates and clinical outcomes of patients treated with neurothrombectomy, we searched the CNKI (China National Knowledge Infrastructure), CBM (Chinese Biomedical Literature), MEDLINE and EMBASE databases to 2011 and summarized the outcome data of patients with acute ischemic stroke treated with neurothrombectomy. Forty-six studies (1530 patients) that reported recanalization rates were included in this analysis. Recanalization rates were recorded for the following neurothrombectomy techniques: endovascular thrombectomy (43-100%, median 86%), endovascular thromboaspiration (67-100%, median 83%), laser thrombolysis (41-50%, median 45.5%), and ultrasonification (62-71%, median 66.5%); the respective rates of symptomatic and asymptomatic intracranial hemorrhage were 20%, 22.5%, 12%, and 19% for each of the four types of neurothrombectomy. Clinical outcome data categorized by success or failure in achieving recanalization were available from 12 articles pertaining to 443 patients. At three months, patients in whom recanalization was achieved had better functional outcomes compared to non-recanalized patients (odds ratio [OR], 5.58; 95% confidence interval [CI], 2.98-10.45). In addition, the three-month mortality was lower in recanalized patients (OR, 0.37; 95% CI, 0.24-0.57). Among the various treatments for acute ischemic stroke, neurothrombectomy appears the most promising. Neurothrombectomy devices show great potential in improving functional outcomes and reducing mortality in patients with acute ischemic stroke, and meta-analysis confirms that successful recanalization was the most important indicator of predicting clinical benefit.
机译:神经血栓切除术正越来越多地用于治疗急性缺血性中风。为了评估接受神经血栓切除术的患者的再通率和临床结局,我们检索了截至2011年的CNKI(中国国家知识基础设施),CBM(中国生物医学文献),MEDLINE和EMBASE数据库,并总结了急性缺血性脑卒中患者的结局数据与神经血栓切除术。这项分析包括46项报告了再通率的研究(1530例患者)。记录了以下神经血栓切除术的再通率:血管内血栓切除术(43-100%,中位数86%),血管内血栓抽吸术(67-100%,中位数83%),激光溶栓术(41-50%,中位数45.5%)和超音波检查(62-71%,中位数66.5%);四种类型的神经血栓切除术中,有症状和无症状颅内出血的发生率分别为20%,22.5%,12%和19%。可从涉及443例患者的12篇文章中获得按再通成功的成功或失败分类的临床结果数据。在三个月时,实现了再通的患者比未再通的患者具有更好的功能结局(优势比[OR]为5.58; 95%置信区间[CI]为2.98-10.45)。此外,再通管患者的三个月死亡率较低(OR,0.37; 95%CI,0.24-0.57)。在急性缺血性卒中的各种治疗方法中,神经血栓切除术似乎是最有希望的。神经血栓切除术设备在改善急性缺血性中风患者的功能结局和降低死亡率方面显示出巨大潜力,荟萃分析证实,成功的再通是预测临床获益的最重要指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号